BillionToOne, Inc. research snapshot
BLLN AI stock analysis currently reads BillionToOne as a high-growth precision diagnostics company with a proprietary single-molecule counting platform serving prenatal and oncology markets. The analysis is not a certain price prediction. At the July 12, 2026 cutoff, the latest verified close used here was $126.77, market capitalization was about $5.83 billion, and the main question was whether the company can sustain its rapid revenue growth, expand reimbursement, and compete against well-funded rivals including Natera and Guardant Health without the stock price already embedding those expectations at roughly 230x trailing earnings. This is informational research and not investment advice.
Current price
$126.77
Market cap
$5.83 billion
AI score
52 / 100
Rating
High-growth diagnostics, priced for perfection
Trend status
Strong uptrend from 2025 IPO, near 52-week highs
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | BillionToOne sells precision diagnostic tests based on its proprietary single-molecule counting platform. Revenue comes from two segments: prenatal screening (Unity NIPT) and oncology liquid biopsy (Northstar). The business has product-market fit in both markets with accelerating revenue. | Medium-high |
| Moat | The moat comes from proprietary smNGS technology, a foothold in both prenatal and oncology testing markets, and growing clinical validation data. However, competitors like Natera, Guardant Health, and Tempus have far larger resources and market presence. | Low-medium |
| Management | CEO Oguzhan Atay (co-founder) and CTO David Tsao (co-founder) are scientists with deep domain expertise. The CFO Ross Taylor brings public company experience. Management raised over $325M in private funding and successfully navigated the 2025 IPO. | Medium |
| Financial trend | Q1 FY2026 revenue was $108.4 million and net income was $21.8 million, up sharply from prior periods. The company recently turned profitable and raised full-year 2026 guidance. Cash position is strong at $537.4 million. | Medium-high |
| Valuation | The stock trades at about 230x TTM earnings and 16.5x TTM revenue. Even for a high-growth diagnostics company, this leaves almost no room for execution missteps. The margin of safety is thin or negative by traditional measures. | Medium |
| Technical trend | BLLN is in a strong uptrend since early 2026, trading well above its 20-day, 50-day, and 100-day moving averages. The 14-day RSI at 67 indicates bullish momentum that is not yet overbought. ADX around 33 suggests a trending market. | Medium |
| Risk level | Key risks include extreme valuation (230x PE), intense competition from much larger players, limited public track record, reimbursement uncertainty, potential insider selling post-IPO lockup, and technology obsolescence risk. | Medium-high |
| AI confidence | Medium-high confidence for recent financial data and competitive landscape. Lower confidence for long-term projections because the public trading history is too short for pattern analysis. | Medium-high data confidence |
| Investment certainty | Low. The business opportunity is real and the growth is impressive, but the entry price at 230x earnings means the investor is paying for many years of perfect execution. | Low |
BLLN AI stock forecast
The BLLN AI stock forecast uses scenario ranges around the $126.77 cutoff price. It does not claim that AI can predict a specific future price. The bullish case requires sustained revenue growth above 30%, expanding profit margins, and successful market share gains in both prenatal and oncology segments. The base case assumes strong growth continues but the valuation multiple contracts as the market prices in competitive pressure. The bearish case assumes growth slows and the stock re-rates significantly lower.
$160 to $195
More likely if BLLN sustains 35%+ revenue growth, turns profitable at scale, wins broad Medicare/insurance reimbursement for Northstar and Unity Confirm, and the market assigns a forward P/S multiple above 20x reflecting its platform value.
$110 to $140
More likely if revenue grows at 20-25%, the company gradually improves margins, competition from Natera and Guardant caps market share, and the stock holds a P/S ratio in the 14-18x range.
$60 to $90
More likely if competitive pressure intensifies, reimbursement expansion stalls, earnings growth disappoints, or the market re-rates the stock closer to established diagnostics peers at single-digit P/S multiples.
BLLN AI technical analysis
BLLN AI technical analysis starts from the $126.77 July 10 close used for this July 12 static page. Barchart public technical data showed the stock above its 20-day ($112.65), 50-day ($98.75), and 100-day ($88.55) moving averages, with 14-day RSI at 67.07 and ADX at 33.05 indicating a trending market. The 200-day moving average is not yet available due to BLLN short trading history since its 2025 IPO. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $126.77 | Latest verified close used for this page as of the July 12, 2026 data cutoff. |
| Near support | $112 to $115 | The 20-day moving average area around $112.65. Barchart data shows this as the first support level during pullbacks. |
| Secondary support | $95 to $100 | The 50-day moving average area around $98.75. A sustained break below this level would weaken the intermediate-term trend. |
| Near resistance | $135 to $139 | The 52-week high zone around $138.70. Breakout attempts above this level would need volume confirmation from the average 710,000+ daily shares. |
| 20-day moving average | About $112.65 | Barchart showed BLLN well above its 20-day MA, with the stock up 27.72% over that period, indicating strong short-term momentum. |
| 50-day moving average | About $98.75 | The 50-day MA shows the stock gained 62.05% over the period, confirming a strong intermediate uptrend. |
| 100-day moving average | About $88.55 | Public technical data showed the stock up 43.07% over the 100-day period, with the MA sloping upward. |
| Momentum | 14-day RSI 67.07, ADX 33.05 | The 14-day RSI at 67.07 is in bullish territory but not yet overbought. The 14-day ADX at 33.05 with +DI of 26.36 and -DI of 11.14 indicates a strong uptrend. |
| Volume | About 711,000 shares daily average | The 20-day average volume was about 761,960 shares, with 5-day average at 730,840. Volume should confirm any breakout attempt. |
| Volatility | 14-day ATR near $7.14 | The 14-day ATR of $7.14 (5.63% of price) means position sizing should allow for normal daily movement around the cutoff price. 14-day historical volatility was 48.79%. |
| Invalidation | Close below $112, then $99 | A close below the 20-day MA weakens the near-term setup. A break below the 50-day MA would challenge the intermediate uptrend. |
BLLN AI trading strategy
The BLLN AI trading strategy is a rules-based framework, not personalized advice. It combines business evidence from recent financials, technical confirmation from moving averages and momentum indicators, position sizing, and clear invalidation levels.
Look for BLLN to hold above the 20-day MA around $112.65 and break the $138.70 52-week high with improving volume. The strong ADX reading supports trend continuation if these conditions hold.
A daily close below the 20-day MA area would reduce confidence. Position size should account for the 5.6% daily ATR range.
If BLLN pulls back toward the $112 to $115 support zone without a fundamental thesis break, look for price stabilization with declining volume before considering entry.
Do not buy the dip solely because of past growth momentum. Monitor Q2 FY2026 results, reimbursement developments, and competitive announcements.
Track Q2 FY2026 revenue and earnings, Unity Confirm adoption metrics, Northstar Select oncology reimbursement progress, competitive market share data, and insider trading activity post-IPO.
Reduce exposure if revenue growth decelerates below 20% YoY or if a major competitor launches a directly comparable product at a lower price point.
Investment research summary
BillionToOne uses its proprietary single-molecule counting platform to sell precision diagnostic tests in two large and growing markets: prenatal screening and oncology liquid biopsy. Customers pay per test, and repeat volume depends on clinical utility and insurance coverage.
The technology moat comes from the smNGS platform that enables detection at single-molecule resolution. But the competitive landscape includes Natera, Guardant Health, Tempus, and GRAIL, all with far larger resources, established provider relationships, and broader test menus.
The thesis can fail if the smNGS technology advantage proves temporary, if larger competitors crush pricing, if reimbursement does not materialize for new tests, if the IPO lockup expiration triggers insider selling, or if the market simply decides 230x earnings is too high.
Founder-led management with deep scientific credentials. CEO Atay and CTO Tsao have built the platform from scratch. The CFO brings public company experience. Key-person risk exists around the founders, but the recent addition of experienced pharma/diagnostics executives strengthens the bench.
Precision diagnostics sits at the intersection of genomics, AI, and personalized medicine. Both the NIPT market and the oncology liquid biopsy market are growing at 10-20% CAGR. The overall trend is favorable, but competition is intense with well-capitalized incumbents.
At roughly 230x TTM earnings and 16.5x TTM revenue, the stock price already bakes in years of aggressive growth and margin expansion. The margin of safety is minimal by traditional value metrics, even if the business opportunity is real.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| BLLN price | $126.77 close on July 10, 2026 | Yahoo Finance quote snapshot | July 12, 2026 |
| Market capitalization | $5.83 billion, verified as $126.77 x 45,980,000 shares | financial_rigor.py market cap verification and Yahoo Finance shares data | July 12, 2026 |
| Q1 FY2026 revenue | $108.4 million | BillionToOne Q1 FY2026 earnings release (May 6, 2026) | July 12, 2026 |
| Q1 FY2026 net income | $21.8 million | BillionToOne Q1 FY2026 earnings release (May 6, 2026) | July 12, 2026 |
| TTM revenue | $354.5 million | Yahoo Finance financial data and SEC filings | July 12, 2026 |
| TTM net income | $24.9 million | Yahoo Finance financial data | July 12, 2026 |
| Cash and cash equivalents | $537.4 million | Yahoo Finance key statistics (MRQ) | July 12, 2026 |
| Shares outstanding | 45.98 million shares | Yahoo Finance key statistics and financial_rigor.py cross-verification | July 12, 2026 |
| 52-week price range | $61.96 to $138.70 | Yahoo Finance statistics | July 12, 2026 |
| Moving averages and momentum | 20-day MA $112.65, 50-day MA $98.75, 100-day MA $88.55, 14-day RSI 67.07, ADX 33.05 | Barchart technical analysis snapshots | July 12, 2026 |
| Valuation math | 230.49x TTM PE, 16.48x TTM PS, 11.57x PB, 0.28% FCF yield from financial_rigor.py | financial_rigor.py valuation verification and Yahoo Finance | July 12, 2026 |
This BLLN AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of July 12, 2026 and can be wrong. BillionToOne has limited public trading history since its 2025 IPO, which reduces the reliability of long-term projections.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
